Compare · CLOV vs NTRA
CLOV vs NTRA
Side-by-side comparison of Clover Health Investments Corp. (CLOV) and Natera Inc. (NTRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CLOV and NTRA operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA is the larger of the two at $47.24B, about 21.6x CLOV ($2.18B).
- Over the past year, CLOV is up 55.3% and NTRA is up 101.6% - NTRA leads by 46.3 points.
- NTRA has been more active in the news (16 items in the past 4 weeks vs 8 for CLOV).
- NTRA has more recent analyst coverage (25 ratings vs 12 for CLOV).
- Company
- Clover Health Investments Corp.
- Natera Inc.
- Price
- $4.10-1.44%
- $327.87-1.19%
- Market cap
- $2.18B
- $47.24B
- 1M return
- -5.09%
- +25.20%
- 1Y return
- +55.30%
- +101.60%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- News (4w)
- 8
- 16
- Recent ratings
- 12
- 25
Clover Health Investments Corp.
Clover Health Investments, Corp. operates as a Medicare Advantage insurer in the United States. The company through its software platform provides preferred provider organization and health maintenance organization health plans for Medicare-eligible consumers. Clover Health Investments, Corp. was founded in 2014 and is headquartered in Franklin, Tennessee.
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Latest CLOV
- Clover Health Investments Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Interim CFO Thornton Joseph Clay sold $78,032 worth of shares (17,775 units at $4.39), decreasing direct ownership by 1% to 1,249,526 units (SEC Form 4) (tax liability)
- Chief Legal Officer Soares Karen was granted 108,695 shares, increasing direct ownership by 7% to 1,614,217 units (SEC Form 4)
- Interim CFO Thornton Joseph Clay was granted 54,347 shares, increasing direct ownership by 4% to 1,267,301 units (SEC Form 4)
- Chief Executive Officer Toy Andrew sold $408,261 worth of shares (87,798 units at $4.65), decreasing direct ownership by 0.92% to 9,459,316 units (SEC Form 4) to satisfy withholding tax
- SEC Form 10-Q filed by Clover Health Investments Corp.
- Clover Health Investments Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Clover Health Reports Second Quarter 2026 Results
- Clover Health to Participate in Upcoming Canaccord Genuity 46th Annual Growth Conference
- Chief Legal Officer Soares Karen sold $233,167 worth of shares (51,700 units at $4.51) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 1,505,522 units (SEC Form 4)
Latest NTRA
- CO-FOUNDER Sheena Jonathan sold $1,951,942 worth of shares (6,000 units at $325.32) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 230,464 units (SEC Form 4)
- Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers
- CO-FOUNDER Sheena Jonathan sold $2,888,325 worth of shares (9,150 units at $315.66) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 236,464 units (SEC Form 4)
- EXECUTIVE CHAIRMAN Rabinowitz Matthew sold $641,800 worth of shares (2,000 units at $320.90) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form S-8 filed by Natera Inc.
- SEC Form 10-Q filed by Natera Inc.
- Natera Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Natera Reports Second Quarter 2026 Financial Results
- PRESIDENT, CHIEF BUS. OFFICER Fesko John sold $79,057 worth of shares (295 units at $267.99) as part of a pre-agreed trading plan, decreasing direct ownership by 0.16% to 183,774 units (SEC Form 4) (for tax liability)
- CHIEF FINANCIAL OFFICER Brophy Michael Burkes sold $216,030 worth of shares (795 units at $271.74) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 51,637 units (SEC Form 4) (withholding obligation)